Trial Profile
A Phase II Study of Eribulin Evaluating Efficacy and Safety as first or secondary line chemotherapy for advanced or metastatic breast cancer without HER2 overexpressing
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Feb 2022
Price :
$35
*
At a glance
- Drugs Eribulin (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 05 Jun 2018 Status changed from recruiting to completed, according to results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 18 Jan 2013 New trial record